{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:19:24Z","timestamp":1771013964942,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,3,7]],"date-time":"2016-03-07T00:00:00Z","timestamp":1457308800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Daiichi Sankyo Pharma Development"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s40262-016-0378-3","type":"journal-article","created":{"date-parts":[[2016,3,7]],"date-time":"2016-03-07T06:55:40Z","timestamp":1457333740000},"page":"1079-1090","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial"],"prefix":"10.1007","volume":"55","author":[{"given":"Elke H. J.","family":"Krekels","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Niebecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats O.","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin E.","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian T.","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrika S. H.","family":"Simonsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siv","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,7]]},"reference":[{"issue":"Suppl 1","key":"378_CR1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1538-7836.2007.02473.x","volume":"5","author":"J Ansell","year":"2007","unstructured":"Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost. 2007;5(Suppl 1):60\u20134.","journal-title":"J Thromb Haemost."},{"key":"378_CR2","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/j.1538-7836.2008.03064.x","volume":"6","author":"T Furugohri","year":"2008","unstructured":"Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6:1542\u20139.","journal-title":"J Thromb Haemost."},{"issue":"5","key":"378_CR3","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1160\/TH11-08-0566","volume":"107","author":"DE Salazar","year":"2012","unstructured":"Salazar DE, Mendell J, Kastrissios H, Green M, Carrothers TJ, Song S, et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost. 2012;107(5):925\u201336.","journal-title":"Thromb Haemost."},{"issue":"8","key":"378_CR4","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1253\/circj.CJ-11-1140","volume":"76","author":"T Yamashita","year":"2012","unstructured":"Yamashita T, Koretsune Y, Yasaka M, Inoue H, Kawai Y, Yamaguchi T, et al. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circ J. 2012;76(8):1840\u20137.","journal-title":"Circ J."},{"key":"378_CR5","first-page":"1124","volume":"49","author":"G Ridout","year":"2009","unstructured":"Ridout G, de la Motte S, Niemczyk S, et al. Effect of renal function on edoxaban pharmacokinetics (PK) and on population PK\/PK\u2013PD model [abstract no. 144]. J Clin Pharmacol. 2009;49:1124.","journal-title":"J Clin Pharmacol."},{"issue":"5","key":"378_CR6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40256-013-0029-0","volume":"13","author":"J Mendell","year":"2013","unstructured":"Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, et al. Drug\u2013drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013;13(5):331\u201342.","journal-title":"Am J Cardiovasc Drugs."},{"issue":"4","key":"378_CR7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","volume":"160","author":"CT Ruff","year":"2010","unstructured":"Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160(4):635\u201341.","journal-title":"Am Heart J."},{"issue":"22","key":"378_CR8","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093\u2013104.","journal-title":"N Engl J Med."},{"issue":"9984","key":"378_CR9","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","volume":"385","author":"CT Ruff","year":"2015","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385(9984):2288\u201395.","journal-title":"Lancet."},{"issue":"1","key":"378_CR10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341.","journal-title":"Nephron."},{"key":"378_CR11","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/cpdd.53","volume":"2","author":"N Matsushima","year":"2013","unstructured":"Matsushima N, Lee F, Sato T, et al. Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin Pharmacol Drug Dev. 2013;2:358\u201366.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"378_CR12","unstructured":"Oguma T, Masumoto H, Yoshigae Y, et al. LC-MS\/MS bioanalytical method for the determination of edoxaban in human plasma [abstract no. R6377]. AAPS J. 2010;S2."},{"key":"378_CR13","unstructured":"Beal S, Sheiner L, Boeckmann A. NONMEM users guides. Ellicott City: ICON Development Solutions; 1989\u20132006."},{"key":"378_CR14","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1038\/psp.2013.24","volume":"2","author":"RJ Keizer","year":"2013","unstructured":"Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol. 2013;2:e50.","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"5","key":"378_CR15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481\u2013504.","journal-title":"J Pharmacokinet Pharmacodyn."},{"issue":"6","key":"378_CR16","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/bcp.12727","volume":"80","author":"R Niebecker","year":"2015","unstructured":"Niebecker R, J\u00f6nsson S, Karlsson MO, Miller R, Nyberg J, Krekels EH, et al. Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and\/or pulmonary embolism-the Hokusai-VTE phase 3 study. Br J Clin Pharmacol. 2015;80(6):1374\u201387.","journal-title":"Br J Clin Pharmacol."},{"issue":"2","key":"378_CR17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J."},{"issue":"11","key":"378_CR18","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00228-014-1736-4","volume":"70","author":"OQ Yin","year":"2014","unstructured":"Yin OQ, Tetsuya K, Miller R. Edoxaban population pharmacokinetics and exposure\u2013response analysis in patients with non-valvular atrial fibrillation. Eur J Clin Pharmacol. 2014;70(11):1339\u201351.","journal-title":"Eur J Clin Pharmacol."},{"issue":"5","key":"378_CR19","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1160\/TH12-03-0184","volume":"108","author":"S Rohatagi","year":"2012","unstructured":"Rohatagi S, Mendell J, Kastrissios H, Green M, Shi M, Patel I, et al. Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery. Thromb Haemost. 2012;108(5):887\u201395.","journal-title":"Thromb Haemost."},{"issue":"8","key":"378_CR20","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/jcph.306","volume":"54","author":"S Song","year":"2014","unstructured":"Song S, Kang D, Halim AB, Miller R. Population pharmacokinetic-pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatment. J Clin Pharmacol. 2014;54(8):910\u20136.","journal-title":"J Clin Pharmacol."},{"issue":"11","key":"378_CR21","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/jcph.541","volume":"55","author":"S J\u00f6nsson","year":"2015","unstructured":"J\u00f6nsson S, Simonsson US, Miller R, Karlsson MO. Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study. J Clin Pharmacol. 2015;55(11):1268\u201379.","journal-title":"J Clin Pharmacol."},{"key":"378_CR22","unstructured":"Daiichi Sankyo Inc.; The TIMI Study Group. Global study to assess the safety and effectiveness of edoxaban (DU-176b) vs standard practice of dosing with warfarin in patients with atrial fibrillation (EngageAFTIMI48) [ClinicalTrials.gov identifier NCT00781391]. US National Institutes of Health, ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov . Accessed 9 Feb 2016."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0378-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-016-0378-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0378-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T04:19:51Z","timestamp":1692245991000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-016-0378-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,7]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["378"],"URL":"https:\/\/doi.org\/10.1007\/s40262-016-0378-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,7]]}}}